3SJAM G, CORNELIS F M S, MARTINE M H, et al. Prognostic value of the plasminogen activation system in patients with gastric carcinoma[J]. Cancer, 1996, 77:1 035-1 043.
5TETU B, BRISSON J, LAPOINTE H, et al. Prognostic significance of stromelysin- 3, geatinase A, and urokinase expression in breast cancer[J]. Human Pathology, 1998, 29 : 979- 985.
6XING R H, RABBANI S A. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion,growth and metastasis[J]. Int J Cancer, 1996, 67:423 -429.
7SLIUTZ G, EDER H, KOELBL H, et al. Quantification of uPA receptor expression in human breast cancer cell lines by CRT -PCR[J]. Breast Cancer Research and Treatment, 1996, 40:257 - 263.
8G RONDAHL- HANSEN J, HILSENBECK S G, CHRISENSEN I J, et al. Prognostic significance of PAI- 1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients[J ].Breast Cancer Research and Treatment, 1997, 43:153 - 163.
9CHO J Y, CHUNG H C, NOH S H, et al. High level of urokinase- type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer, 1997. 78:878 - 883.
10MAEDA K, CHUNG Y S, SAWADA T, et al. Combined evaluation of urokinase- type plasminogen activator and plasminogen activator inhibitor - 2 expression in gastric carcinoma[J]. IntJ Oncology, 1996, 8: 499-503.
3[1]Dano K, Andresson PA, Grondahl-Hasen J, et al. Plasminogen activitor, tissue degradation and cancer. Adv Cancer Res, 1985; 44(1):139.
4[2]Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: animbalance of positive and negative regulation. Cell, 1991; 64(2):327.
5[3]Macchione E, Epifano O, Stefanini M, et al. Urokinase redistribution from the secreted to cell-bound fraction in granulosa cells of rat preovulatory follicles. Biol Reprod, 2000; 62(4):895.
6[4]Ossowski L. in vivo invasion of modified chorioallantoic membrane by tumor cell: the role of cell surface-bound urokinase. J Cell Biol, 1988; 107(6 pt 1):2437.
7[5]Hofmann R, Lehmer A, Hartung R, et al. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol, 1996; 155(3):858.
8Dano K, Andreason PA, Grondahl-Hasen, et al. Plasminogen activitor, tissue degradation and cancer[J]. Adv Cancer Res,1985, 44:139.
9Bouchet C, Spyrators F, Martis PM, et al. Prognostic value of urokinase-type plasminogen activator and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas[J], Br J Cancer, 1994,199:179.
10Del Vecchio S, Stoppeli MP, Carriero MV, et al. Human urokinase receptor concentration in malign and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels[J]. Cancer Res, 1993,53 : 3198.
4Folkman J. What is the evidence that tumors are mlgiogenesis dependent? J Natl Cancer Inst, 1990,82(1 ) :4
5Risau W.Mechanisms of angiogenesis. Nature, 1997,386 : 671
6Andreasen PA, Kjoller L, Christensen L et al . The urokinase - type plasminogen activator system in cancer metastasis: a review. Int J Cancer, 1997,72( 1 ) : 1
7Ulrich JK, Christian H, Bjorn WL. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol, 2003,06 (5):471
8Macchione E, Epifano O, Stefanini M et al . Urokinase redistribution from the cell- bound fraction in granulose cells of rat preovulatory follicles. Biol Reprod, 2000,62: 895
9Masataka U, Kazuo S, Hisazumi I. Expression of vascular endothelial growth factor and prognosis of oral squamous cell carcinoma. Oral Oncology,2004,40(8 ) :321
10Penny L, Ursula H. Vascular endothelial growth factoy production and regulation in rodent and human pituitary tumor cell in vitro. Neuroendocrinology, 2001,74(6 ) : 95
